MY148092A - Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease - Google Patents

Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Info

Publication number
MY148092A
MY148092A MYPI20094343A MYPI20094343A MY148092A MY 148092 A MY148092 A MY 148092A MY PI20094343 A MYPI20094343 A MY PI20094343A MY PI20094343 A MYPI20094343 A MY PI20094343A MY 148092 A MY148092 A MY 148092A
Authority
MY
Malaysia
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
parkinson
dichloro
Prior art date
Application number
MYPI20094343A
Other languages
English (en)
Inventor
Delay-Goyet Philippe
Delgorge Claire
Menet Christine
Poughon Gilles
Ravinet-Trillou Christine
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY148092A publication Critical patent/MY148092A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MYPI20094343A 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease MY148092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
MY148092A true MY148092A (en) 2013-02-28

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20094343A MY148092A (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Country Status (33)

Country Link
US (1) US20100130554A1 (cg-RX-API-DMAC7.html)
EP (1) EP2146714B1 (cg-RX-API-DMAC7.html)
JP (1) JP5386478B2 (cg-RX-API-DMAC7.html)
KR (2) KR101503942B1 (cg-RX-API-DMAC7.html)
CN (1) CN101663035B (cg-RX-API-DMAC7.html)
AR (1) AR066108A1 (cg-RX-API-DMAC7.html)
AT (1) ATE513548T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008257322B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810444A2 (cg-RX-API-DMAC7.html)
CA (1) CA2684174C (cg-RX-API-DMAC7.html)
CL (1) CL2008001136A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111840T1 (cg-RX-API-DMAC7.html)
DK (1) DK2146714T3 (cg-RX-API-DMAC7.html)
EA (1) EA019194B1 (cg-RX-API-DMAC7.html)
ES (1) ES2367408T3 (cg-RX-API-DMAC7.html)
FR (1) FR2915100B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20110666T1 (cg-RX-API-DMAC7.html)
IL (1) IL201448A (cg-RX-API-DMAC7.html)
JO (1) JO2678B1 (cg-RX-API-DMAC7.html)
MA (1) MA31367B1 (cg-RX-API-DMAC7.html)
ME (1) ME00935B (cg-RX-API-DMAC7.html)
MX (1) MX2009011284A (cg-RX-API-DMAC7.html)
MY (1) MY148092A (cg-RX-API-DMAC7.html)
NZ (1) NZ580482A (cg-RX-API-DMAC7.html)
PA (1) PA8776801A1 (cg-RX-API-DMAC7.html)
PL (1) PL2146714T3 (cg-RX-API-DMAC7.html)
PT (1) PT2146714E (cg-RX-API-DMAC7.html)
RS (1) RS51869B (cg-RX-API-DMAC7.html)
SI (1) SI2146714T1 (cg-RX-API-DMAC7.html)
TW (1) TWI439269B (cg-RX-API-DMAC7.html)
UY (1) UY31035A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008145841A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907251B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150087252A (ko) * 2012-11-28 2015-07-29 사노피 4-(사이클로프로필메톡시)-n-(3,5-디클로로-1-옥시도피리딘-4-일)-5-메톡시피리딘-2-카복스아미드의 결정 형태의 제조 방법 및 이의 결정 형태
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DK0711282T3 (da) * 1993-07-28 2002-09-16 Aventis Pharma Ltd Forbindelser som PDE IV og TNF inhibitorer
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンpde4阻害剤
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
ES2367408T3 (es) 2011-11-03
ME00935B (me) 2012-06-20
CA2684174A1 (fr) 2008-12-04
MX2009011284A (es) 2009-11-02
JP5386478B2 (ja) 2014-01-15
ATE513548T1 (de) 2011-07-15
EP2146714A1 (fr) 2010-01-27
EA019194B1 (ru) 2014-01-30
CL2008001136A1 (es) 2009-01-16
SI2146714T1 (sl) 2011-10-28
ZA200907251B (en) 2011-04-28
RS51869B (sr) 2012-02-29
CA2684174C (fr) 2014-02-25
EA200970970A1 (ru) 2010-02-26
KR20090130059A (ko) 2009-12-17
IL201448A (en) 2014-08-31
CN101663035A (zh) 2010-03-03
HRP20110666T1 (hr) 2011-10-31
FR2915100B1 (fr) 2009-06-05
MA31367B1 (fr) 2010-05-03
UY31035A1 (es) 2008-11-28
FR2915100A1 (fr) 2008-10-24
HK1141725A1 (en) 2010-11-19
WO2008145841A1 (fr) 2008-12-04
KR20150004885A (ko) 2015-01-13
JO2678B1 (en) 2013-03-03
TWI439269B (zh) 2014-06-01
TW200911247A (en) 2009-03-16
EP2146714B1 (fr) 2011-06-22
CY1111840T1 (el) 2015-10-07
US20100130554A1 (en) 2010-05-27
AU2008257322B2 (en) 2013-06-13
JP2010524906A (ja) 2010-07-22
CN101663035B (zh) 2012-06-20
KR101503942B1 (ko) 2015-03-18
PA8776801A1 (es) 2008-11-19
AU2008257322A1 (en) 2008-12-04
AR066108A1 (es) 2009-07-22
PT2146714E (pt) 2011-09-02
NZ580482A (en) 2011-10-28
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
PL2146714T3 (pl) 2011-10-31
IL201448A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MY150931A (en) Substituted oxazolidinones and their use
WO2008104590A3 (en) Novel dosage form
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
MX2009009361A (es) Nueva forma de dosificacion.
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
UA96278C2 (ru) Применение флибансерина для лечения расстройств полового влечения в предклимактерический период
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
UA94466C2 (ru) Комбинированные препараты с содержанием slv308 и l-dopa
UA94465C2 (ru) Комбинированные препараты с содержанием бифепрунокса и l-dopa